Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Final Results

30 Sep 2010 07:00

30 September 2010 STERLING GREEN GROUP PLC ("Sterling Green" or "the Company") Final Results for the year ended 31 March 2010

CHAIRMAN'S STATEMENT

Introduction and review of activities

I am pleased to present the final results of Sterling Green Group plc and its subsidiaries ("the Group") covering the year ended 31 March 2010.

Results and dividends

Revenue for the year ended 31 March 2010 was £2,106,000 (2009 - £1,966,000), which was made up of £1,977,000 (2009 - £1,609,000) from debt management services and £129,000 (2009 - £357,000) relating to mortgage business.

The Group loss after taxation for the year amounted to £238,000 (2009 - £ 347,000). The Directors are not able to recommend the payment of a dividend.

Trading review

Following the release in November 2009 of encouraging interim results for the first half of the financial year, the second half proved to be very disappointing, as the Group was unable to generate an operating profit for the year as a whole. Although debt management revenues for the year increased by 22.9% compared to the previous year, revenues fell short of management expectations for the second half of the financial year, in particular in the final quarter, as the sign up of new customers slowed considerably. This had a great deal to do with inconsistencies in the quality of leads from our external lead generators which affected our conversion ratios. Mortgage business remained very subdued during the year, in which there was a considerable 63.9% fall in revenues.

Gross margins improved from 45.6% in 2009 to 46.4% for the current year, while administration costs reduced by 6.2% compared to the previous year as the Board continued to monitor and control Group overheads.

Current performance and future developments

The lead supply problems experienced earlier this year have now been addressed as a number of new reliable lead providers have been sourced and evaluated, which provides the Group with leads in appropriate quantities and of suitable quality. While there is no guarantee that these arrangements will continue for the long term, the Board believes that the appointment of an increased number of reliable lead suppliers is a significant step forward for the Group in the development of its current business model. Certainly the early signs for the new financial year have been very encouraging, with the Group already adding over 700 new clients since 31 March 2010 compared to 792 for the whole of the previous year.

The mortgage industry remains very subdued. For the short term, the Board does not envisage any improved revenue activity in this area and accordingly it continues to monitor the contribution being made by this activity to the Group's trading performance.

The Group's working capital position remains challenging. However, the rising value of the Group's client portfolio, which is not recorded as an asset in the Group's accounts, has enabled the Board to renew the Group's external loan facilities to 30 September 2011. The Group is currently operating within these borrowing facilities and based on forecasts prepared for the period ending 31 March 2012, management remain confident that this situation will continue throughout the forecast period.

Trading in the period since 31 March 2010 has been marginally profitable at theGroup level and the Board continue to look at ways of increasing revenues andprofitability.J M EdelsonChairman30 September 2010Further enquiries:Sterling Green Group plc Tel: 0161 975 5757 Michael Edelson Merchant Securities Limited Tel: 020 7628 2200 Simon Clements/David Worlidge

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 MARCH 2010

Note 2010 2009 £000 £000 Revenue 2,106 1,966 Cost of sales (1,128) (1,069) Gross profit 978 897 Administrative expenses (1,143) (1,218) Loss from operations (165) (321) Investment income - 5 Finance costs (72) (49) Loss before tax (237) (365) Income tax (charge)/credit 2 (1) 18 Loss for the year and loss attributable (238) (347)to equity holders of the parent Loss per share Basic and diluted 3 (0.08p) (0.12p)

There were no other items of comprehensive income other than the loss for the year.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2010

2010 2009 £000 £000 Non-current assets Intangible assets 1,115 1,115 Property, plant and equipment 116 209 Total non-current assets 1,231 1,324 Current assets Trade and other receivables 108 142 Cash and cash equivalents 28 182 Total current assets 136 324 Current liabilities Trade and other payables (361) (319) Current tax liabilities (1) - Borrowings (39) (86) Total current liabilities (401) (405) Net current liabilities (265) (81) Non-current liabilities Borrowings (279) (318) Total non-current liabilities (279) (318) Net assets 687 925 Equity attributable to the owners of the parent Called up share capital 304 288 Share premium account 1,794 1,710 Share capital to be issued - 100 Capital reserve 6 6 Other reserve 891 891 Accumulated losses (2,308) (2,070) Total equity 687 925

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2010

Note 2010 2009 £000 £000 Cash flows from/(used in) operating activities Loss before tax (237) (365) Adjustments for: Depreciation of property, plant and equipment 98 101 Investment income - (5) Finance costs 72 49 Operating cash flows before movement in working (67) (220)capital Decrease/(Increase) in trade and other 34 (1)receivables Increase in trade and other payables 42 1 Net cash from/(used in) operating activities 9 (220) Cash flows (used in)/from investing activities Investment income received - 5 Purchase of property, plant and equipment (5) (1) Net cash (used in)/from investing activities (5) 4 Cash flows (used in)/from financing activities Capital element of lease payments (86) (85) Loans advanced - 250 Issue of ordinary share capital - 200 Proceeds in advance of issue of share capital - 100 Finance costs paid (72) (49) Net cash (used in)/from financing activities (158) 416 Net (decrease)/increase in cash and cash (154) 200equivalents Cash and cash equivalents at the start of the 182 (18)year Cash and cash equivalents at the end of the year 4 28 182

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 MARCH 2010

Attributable to equity holders of the parent Share Share Share Capital Other Accumulated Total capital premium capital reserve reserve losses account to be issued £000 £000 £000 £000 £000 £000 £000 At 1 April 2008 280 1,518 - 6 891 (1,723) 972 Loss for the year - - - - - (347) (347) Issue of share 8 192 - - - - 200capital Share capital to be - - 100 - - - 100issued

At 31 March 2009 288 1,710 100 6 891 (2,070) 925

Loss for the year - - - - - (238) (238)

Issue of share 16 84 (100) - - - -capital

At 31 March 2010 304 1,794 - 6 891 (2,308) 687

Other reserve

The other reserve is a merger reserve created on the acquisition of Sterling Green Limited.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2010

1. Basis of preparation

The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as adopted by the European Union and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS.

The financial information set out above does not constitute the Company's statutory financial statements for the years ended 31 March 2009 and 31 March 2010, but is derived from those financial statements. The Auditors have reported on those financial statements; their reports were unqualified and did not contain statements under the Companies Act 1985, sections 237(2) or (3). The statutory accounts for the year ended 31 March 2009 have been delivered to the Registrar of Companies, whereas those for the year ended 31 March 2010 will be delivered in due course.

The Board has considered the Group's financial position and trading prospects using detailed forecasts covering the period ending 31 March 2012. Those forecasts incorporate the current drawn down loan facility which is confirmed as available until 30 September 2011. There are no financial covenants attached to that facility. Accordingly, the Board considers that there will be no breaches of financial covenants during the period to 30 September 2011. Having made appropriate consideration, the Board believes that it has adequate resources to continue trading for the foreseeable future, and accordingly, the going concern basis has been adopted in preparing these financial statements.

2. Income tax (charge)/credit 2010 2009 £000 £000 Current year tax: UK corporation tax - 18 Prior year tax: UK corporation tax underprovided (1) - (1) 18

Corporation tax is calculated at 28% (2009 - 28%) of the estimated assessable loss for the year.

The tax (charge)/credit for the year can be reconciled to the consolidated statement of comprehensive income as follows:

2010 2009 £000 £000 Loss before tax (237) (365) Loss on ordinary activities multiplied by the (66) (102)relevant standard rate of corporation tax in the UK of 28% (2009 - 28%) Effect of: Expenses not deductible for tax purposes 4 6 Depreciation for year in excess of capital 4 28allowances Utilisation of losses - 18 Losses carried forward 58 68 UK Corporation tax underprovided in prior year (1) - Total tax (charge)/credit for the year (1) 18

Unrecognised deferred tax assets

The following deferred tax assets have not been brought into account as assets:

2010 2009 £000 £000 Tax losses 534 476 Temporary differences 60 563. Loss per share

The calculation of basic loss per share is based on the following:

Basic 2010 2009 Loss for the year (£000) (238) (347) Weighted average number of shares 303,587,719 287,569,637 Loss per share (pence) (0.08) (0.12)

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue assuming conversion of all dilutive potential ordinary shares. During the year the Company's potential ordinary shares consist of share options. Due to losses in the current and preceding year there are no dilutive ordinary shares.

4. Notes to the cashflow statement

Cash and cash equivalents

Cash and cash equivalents consist of bank balances. Cash and cash equivalents included in the cash flow statement comprise the following amounts:

2010 2009 £000 £000 Cash at bank 28 1825. Related party transactions

The services of J M Edelson were provided to the Group under a service agreement by London & City Credit Corporation Limited. Amounts charged to the Group during the year for his services amounted to £25,000 (2009 - £25,000). At 31 March 2010 £2,448 (2009 - £nil) of this amount remained outstanding.

S. T. Ali and J. McClean have provided personal guarantees as security for £ 250,000 of the loan facility available to the Group.

6. Dividend

The directors are not able to recommend the payment of a dividend.

7. Copies of the Report & Accounts

Copies of the Report & Accounts will be posted to shareholders shortly and are also available from the Company's registered office at Number 14, The Embankment, Vale Road, Heaton Mersey, Stockport, Cheshire SK4 3GN and from the Company's website www.sterlinggreen.co.uk.

38

vendor
Date   Source Headline
4th Mar 202112:00 pmRNSAmryt Announces Record FY 2020 Results
25th Feb 20217:00 amRNSAmryt Supports Global Rare Disease Day 2021
24th Feb 20217:00 amGNWAmryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10th Feb 20217:00 amRNSAmryt to Present at SVB Leerink Conference
4th Feb 20217:00 amGNWAmryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20th Jan 20217:00 amGNWAmryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6th Jan 20217:00 amRNSAmryt to present at H.C Wainwright Conference
23rd Dec 20207:00 amGNWAmryt Granted Orphan Drug Designation by the FDA for AP103
17th Dec 20207:00 amGNWAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11th Dec 202010:00 amGNWHolding(s) in Company
9th Dec 20202:45 pmGNWHolding(s) in Company
9th Dec 20207:00 amGNWAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
8th Dec 20207:00 amGNWAmryt Announces $40m Private Placement with Leading Biotech Investors
5th Nov 202012:00 pmGNWAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29th Oct 20207:00 amGNWAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
19th Oct 20207:00 amGNWAmryt and Swixx Sign Distribution Deal for Lojuxta
14th Oct 20207:00 amRNSAMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020
14th Oct 20207:00 amGNWNotice of Results
12th Oct 202011:00 amGNWHolding(s) in Company
9th Oct 20207:00 amGNWVirtual Analyst & Investor Event - Tuesday November 3, 2020
8th Oct 20207:00 amGNWAMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
1st Oct 20207:00 amGNWExercise of Options and Total Voting Rights
30th Sep 202012:30 pmGNWHolding(s) in Company
23rd Sep 20207:00 amRNSAMRYT SUPPORTS GLOBAL FH AWARENESS DAY
21st Sep 202011:00 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
15th Sep 20207:00 amRNSPOSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION
9th Sep 20202:05 pmRNSSecond Price Monitoring Extn
9th Sep 20202:00 pmRNSPrice Monitoring Extension
9th Sep 20207:00 amRNSPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
11th Aug 202011:09 amRNSCANCELLATION OF ADMISSION TO EURONEXT GROWTH
7th Aug 20207:00 amRNSAMRYT PRESENTING AT CANACCORD GENUITY CONFERENCE
6th Aug 202012:00 pmRNSAMRYT ANNOUNCES Q2 2020 RESULTS
29th Jul 20202:30 pmRNSResult of AGM
29th Jul 20207:00 amRNSAMRYT HOSTING KOL CALL ON EB DISEASE LANDSCAPE
20th Jul 20207:00 amRNSAMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
15th Jul 20208:00 amRNSEuronext Growth Dublin Notice
10th Jul 20207:00 amRNSExercise of Warrants & Issue of Ordinary Shares
8th Jul 20203:09 pmRNSAMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL
30th Jun 20207:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
24th Jun 20207:00 amRNSForm F-1 publicly filed for impending US listing
4th Jun 20202:20 pmRNSDirector/PDMR Shareholding
3rd Jun 202011:30 amRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSAMRYT & SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA
11th May 20207:00 amRNSQ1 2020 RESULTS
11th May 20207:00 amRNSFY 2019 RESULTS
7th May 20209:00 amRNSNotice of Results
7th May 20207:00 amRNSFILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101
23rd Apr 20207:00 amRNSEASE CLINICAL STUDY UPDATE
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20207:00 amRNSMarket Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.